You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Sao Paulo state in Brazil asks approval to use Sinovac Covid-19 vaccine

Sao Paulo, Brazil's most populous state, is one of the sites of Phase III clinical trials for the Sinovac vaccine conducted by the state's Butantan Institute, a leading biomedical research center

Topics
Coronavirus Vaccine | Brazil | Coronavirus

Reuters  |  Sao Paulo 

Coronavirus, vaccine, covid, drugs, tests, clinical trials

The government of Sao Paulo state in has asked health regulator Anvisa to register for use the Covid-19 vaccine candidate developed by China's Sinovac Biotech Ltd, governor Joao Doria said on Friday, a major step in what could be one of the first vaccination programs in the Americas.

Doria has said he plans to begin inoculating the population of Sao Paulo with the Sinovac vaccine by mid-December, one of the world's most aggressive timelines outside China and Russia.

Before he is able to do so, he requires approval from Anvisa. Shortly after Doria's statement, the regulator confirmed it had received the first tranche of data related to the Sinovac vaccine.

Sao Paulo, Brazil's most populous state, is one of the sites of Phase III clinical trials for the Sinovac vaccine conducted by the state's Butantan Institute, a leading biomedical research center.

On Wednesday, Sao Paulo signed a $90 million contract on Wednesday to receive 46 million doses of the potential vaccine from Sinovac.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, October 03 2020. 16:45 IST
RECOMMENDED FOR YOU